🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07447011
Recruiting Not applicable

Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea

NCT07447011 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-02-04
Last updated
2026-03-03

Condition(s) studied

Primary Open Angle GlaucomaObstructive Sleep ApneaObesity

Investigational drug(s) / intervention(s)

lifetyle corrections and CPAPCPAP

lifetyle corrections and CPAP: twenty glaucoma patients (high tension priamry open angle form) with OSA, intraocular pressure more than 21 mmHg, and obesity will be involved in group I will apply CPAP during night sleeping daily for three month. group I will apply lifestyle corrections (low calories diet intake and 3-session per-week 40-minute treadmill walking for three month.

CPAP: twenty glaucoma patients (high tension priamry open angle form) with OSA, intraocular pressure more than 21 mmHg, and obesity will be involved in group II will apply CPAP during night sleeping daily for three month.

Study summary

glaucoma is prevalent among obstructive sleep apnea (OSA). contnous passive airway pressure is main treatment of OSA. lifestyle corrections also recommended

Eligibility

Sex
ALL
Min age
30 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Obstructive sleep apnea patients * obese patients * glaucoma (open angle form with ocular hyoertension) Exclusion Criteria: cardiac patients renal patients hepatic patients

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Cairo University Giza Dokki Recruiting

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07447011 on ClinicalTrials.gov ↗ ← All trials in Egypt